로딩 중…
지수 로딩 중…
Ultragenyx Pharmaceutical Inc.
RARE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$25.02+0.44%
2026-08-03
Financials
Valuation Metrics
Ultragenyx Pharmaceutical Inc.'s Market Cap is $2.46B. At end of 2025 it was $2.30B. Ranked #1903 of 3,111 in US market (top 61%), #702 of 1,445 on NASDAQ (top 49%), #115 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.46B | US#1,903/3,111 Sec#115/269 |
| Revenue | $669M | US#2,203/3,111 Sec#71/269 |
| Net Income | $-609M | US—/3,111 Sec—/269 |
| Total Assets | $1.30B | US#2,327/3,111 Sec#81/269 |
| Net Assets | $151M | US#2,812/3,111 Sec#215/269 |
| Value | ||
| P/B | 16.29x | US#2,767/3,111 Sec#224/269 |
| P/S | 3.68x | US#2,007/3,111 Sec#60/269 |
| FCF Yield | -19.77% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROA | -47.02% | US#2,966/3,111 Sec#211/269 |
| Op. Margin | -83.92% | US#2,817/3,111 Sec#121/269 |
| Revenue Growth | -2.36% | US#2,407/3,111 Sec#133/269 |
| Financial Health | ||
| Debt Ratio | 1008.02% | US#2,780/3,111 Sec#246/269 |
| Total Debt | $1.20B | US#1,414/3,111 Sec#40/269 |
| FCF | $-487M | US#2,844/3,111 Sec#260/269 |
| Cash | $175M | US#1,822/3,111 Sec#129/269 |
| Current Ratio | 2.02x | US#1,247/3,111 Sec#229/269 |
| Performance | ||
| 1Y Return | -12.03% | US#2,285/3,111 Sec#210/269 |
| 1M Return | -25.25% | US#2,900/3,111 Sec#244/269 |
| From 52W High | -37.28% | US#2,394/3,111 Sec#188/269 |
| 1Y MDD | -55.36% | US#2,591/3,111 Sec#203/269 |
| Trading | ||
| Volume | 1,992,418 shares | US#1,047/3,111 Sec#97/269 |
| Trading Value | $49M | US#1,502/3,111 Sec#96/269 |
| Per Share | ||
| EPS | $-5.76 | US—/3,111 Sec—/269 |